Oxford Biomedica (OXB) Competitors

Genus (LON:GNS) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Do analysts rate GNS or OXB?

Genus presently has a consensus target price of GBX 2,725, suggesting a potential upside of 4.21%. Oxford Biomedica has a consensus target price of GBX 540.25, suggesting a potential downside of 6.53%. Given Genus' stronger consensus rating and higher possible upside, equities research analysts plainly believe Genus is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Biomedica	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Which has better valuation and earnings, GNS or OXB?

Genus has higher revenue and earnings than Oxford Biomedica. Genus is trading at a lower price-to-earnings ratio than Oxford Biomedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£672.80M	2.55	£7.87M	-£0.06	-42,177.42
Oxford Biomedica	£128.80M	5.39	-£143.51M	-£0.42	-1,384.43

Do insiders and institutionals believe in GNS or OXB?

63.4% of Genus shares are held by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are held by institutional investors. 0.6% of Genus shares are held by company insiders. Comparatively, 43.3% of Oxford Biomedica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Is GNS or OXB more profitable?

Genus has a net margin of 1.18% compared to Oxford Biomedica's net margin of -145.98%. Genus' return on equity of 1.41% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	1.18%	1.41%	3.31%
Oxford Biomedica	-145.98%	-202.50%	-12.67%

Which has more volatility & risk, GNS or OXB?

Genus has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Oxford Biomedica has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

Does the media refer more to GNS or OXB?

In the previous week, Genus had 4 more articles in the media than Oxford Biomedica. MarketBeat recorded 6 mentions for Genus and 2 mentions for Oxford Biomedica. Genus' average media sentiment score of 0.73 beat Oxford Biomedica's score of 0.14 indicating that Genus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genus	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Oxford Biomedica	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Genus beats Oxford Biomedica on 11 of the 15 factors compared between the two stocks.